104 related articles for article (PubMed ID: 7833097)
1. Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.
Gadducci A; Brunetti I; Muttini MP; Fanucchi A; Dargenio F; Giannessi PG; Conte PF
Eur J Cancer; 1994; 30A(10):1432-5. PubMed ID: 7833097
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
[TBL] [Abstract][Full Text] [Related]
3. Lonidamine in high-risk breast cancer patients.
Possinger K; Wagner H; Kovacs S; Flath B; Classen S; Wilmanns W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):58-61. PubMed ID: 2031199
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer.
Redman C; Lawton F; Stuart N; O'Brien M; Buxton J; Mould J; Chetiyawardana A; Crawford M; Patterson M; Sykes V
Cancer Chemother Pharmacol; 1989; 23(1):51-3. PubMed ID: 2491794
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
[TBL] [Abstract][Full Text] [Related]
6. Combination of epirubicin and lonidamine for treatment of advanced breast cancer.
Moraglio L; Brema F; Pastorino G; Martini MC; Vallauri M
Tumori; 1995; 81(2):107-11. PubMed ID: 7778213
[TBL] [Abstract][Full Text] [Related]
7. Weekly epirubicin plus lonidamine in advanced breast carcinoma.
Nisticò C; Garufi C; Milella M; D'Ottavio AM; Vaccaro A; Fabi A; Terzoli E
Breast Cancer Res Treat; 1999 Aug; 56(3):233-7. PubMed ID: 10573114
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
[TBL] [Abstract][Full Text] [Related]
10. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
De Lena M; Lorusso V; Bottalico C; Brandi M; De Mitrio A; Catino A; Guida M; Latorre A; Leone B; Vallejo C; Gargano G
J Clin Oncol; 1997 Oct; 15(10):3208-13. PubMed ID: 9336357
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.
Bolis G; Parazzini F; Scarfone G; Villa A; Amoroso M; Rabaiotti E; Polatti A; Reina S; Pirletti E
Gynecol Oncol; 1999 Jan; 72(1):60-4. PubMed ID: 9889031
[TBL] [Abstract][Full Text] [Related]
12. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
13. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
14. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
[TBL] [Abstract][Full Text] [Related]
15. Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
Lopez M; Vici P; Di Lauro L; Paoletti G; Gionfra T; Conti F; Carpano S; Pignatti F; Giannarelli D
Eur J Cancer; 1995 Sep; 31A(10):1611-4. PubMed ID: 7488410
[TBL] [Abstract][Full Text] [Related]
16. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
18. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
19. Objective response to epirubicin and lonidamine. A case of advanced thymoma previously treated with the ADOC scheme and unresponsive to paclitaxel plus cyclophosphamide.
Berruti A; Tampellini M; Gorzegno G; Dogliotti L
Chest; 1997 May; 111(5):1473-4. PubMed ID: 9149629
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
